When should you ask about the ending?
Bring up the end-of-study plan during the first information discussion, especially if research treatment or frequent visits would become part of your routine. Ask which arrangements are settled and which depend on later approvals or findings. Return to the question before your final planned visit. Distinguish the end of your participation from the end of data collection for everyone: other participants may still be involved. If your schedule changes or the study stops early, ask who will explain the revised plan rather than relying on the date first discussed.
Who will manage your care afterwards?
Ask whether your usual clinician remains responsible throughout, whether the study has provided specific care and what needs to be handed over. Agree who should arrange the next clinical appointment and any necessary documents. Ask what information can be sent to your clinician, with the appropriate permissions, and what summary you can keep. Do not assume an appointment is booked simply because a referral was mentioned. If you do not have a usual clinician, raise that early so you can discuss realistic care routes without assuming the study will arrange ongoing treatment.
Can you continue receiving the study treatment?
Ask what the protocol and approved arrangements allow, who decides and whether any access would have costs or a time limit. A positive experience during the study does not establish a right to an unlimited supply afterwards. Do not assume a separate extension study exists or that you would qualify for one. If access ends, ask the relevant clinicians about the care transition, prescriptions and follow-up. This guide cannot recommend a medicine change. Ask for the plan and the contact responsible for answering treatment questions before the final supply or procedure.
Will you receive your own test results?
Ask which findings are intended for clinical use and which measures are used only for research. A research score, image or laboratory measure may not provide an individual clinical answer. Ask what can be shared, whether a clinician will explain it and how unexpected findings would be handled. You can ask whether a copy or summary can go to your treating clinician. Do not interpret a missing result as good news, bad news or evidence that nothing was measured. The important point is to understand the communication plan for this particular study.
How can you find the overall results?
Keep the study’s registry identifier and ask where a plain-language summary or publication will be available. The NIMH explains that analysis and scientific publication happen after a trial ends; the result is not necessarily ready at your last appointment. A registry update, a journal paper and a summary for participants are different documents. Ask which the team intends to provide and how it will notify you. European medicines-trial reporting has its own framework, described by EMA; do not apply one deadline to every kind of research in every country.
What should you confirm at the last visit?
Write down the next care contact, any agreed follow-up, the treatment plan and who handles later health questions. Separately record the contact for personal findings and overall study results. Ask what to do if your address changes or you no longer want optional research updates. If the explanation is unclear, request a short written summary. Participation can contribute useful evidence without improving every person’s health, so ask for help understanding disappointing or inconclusive findings too. For urgent health needs after the study, use the appropriate care service rather than waiting for a research-results email.